Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$2.4B
128M shares
52-week range
$7.07 – $19.76
91% from low
Sector
SERVICES-TESTING LABORATORIES
Exchange
NASDAQ
CS
P/S (TTM)
0.6
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
www.neogenomics.comNo one on the platform currently holds NEO.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 254,172 | $1.9M |
| Bridgewater Associatesas of 2026-03-31 | 91,190 | $676.6K |
No one on the platform has traded NEO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | 10.1% | 10.4% | ||||
| Profit Margin % | -14.9% | -14.3% | -7.0% | |||
| Free Cash Flow Margin % | -3.0% | -10.2% | -3.8% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +29.1% on the P/E track.
At today's price, your expected annual return is +35.2% on the P/E track.
At today's price, your expected annual return is +40.5% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $804M | +10.8% | $0.18 | $0.16–$0.19 | 102.2× | 7 |
| 2027 | $885M | +10.0% | $0.34 | $0.30–$0.39 | 55.2× | 7 |
| 2028 | $966M | +9.1% | $0.47 | $0.29–$0.78 | 39.9× | 4 |
| 2029 | $1.0B | +6.6% | $0.69 | $0.68–$0.70 | 27.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-28 | $0.03 | $0.05 | +49.0% |
| 2026-04-28 | $0.01 | $0.01 | +73.0% |
| 2026-02-17 | $0.04 | $0.06 | +50.0% |
| 2025-10-28 | $0.02 | $0.03 | +50.0% |
| 2025-07-29 | $0.03 | $0.03 | +0.0% |
| 2025-04-29 | $-0.02 | $-0.08 | -300.0% |
| 2025-02-18 | $0.03 | $0.04 | +33.3% |
| 2024-11-05 | $0.01 |
| $0.05 |
| +316.7% |
| $35M |
| — |
| QTRXQuanterix Corporation | $2.67 | +6.80% | $126M | — |
| SGMTSagimet Biosciences Inc. | $10.47 | -3.78% | $341M | — |
Source: Financial Modeling Prep · peers by sector/industry
$NEO I'm out. Will re-enter if this goes back to 14! Good luck to all the long term holders here!
View on StockTwits ↗
$NEO Took time and at this point $30 will be approaching back to fair value. Still has a way to go. Most interested in where the analyst upgrades will set their new price targets. $NEO has always been an acquisition target. Would like to see management work towards a sale to unlock the true value of their lab offerings. Just think the right acquirer would be able to get much more juice out of their test offerings. Will reevaluate at $30.
View on StockTwits ↗
$NEO $SJM $REPL Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? https://stocktwits.com/news-articles/markets/equity/why-did-sjm-repl-neo-stocks-surge-to-52-week-highs-today/cZY8nHBRJpL
View on StockTwits ↗
Why Did SJM, REPL, NEO Stocks Surge To 52-Week Highs Today? $SJM $REPL $NEO https://stocktwits.com/news/equity/markets/why-did-sjm-repl-neo-stocks-surge-to-52-week-highs-today/cZY8nHBRJpL
View on StockTwits ↗
$NEO Upward!!! Does Suckstory have a response to the Medicare Coverage for RaDaR ST!!!
View on StockTwits ↗
$NEO Holy smokes, Suckstory...are you just caught short and trying to save your sinking position???
View on StockTwits ↗
Wall St is expecting 0.05 EPS for $NEO Q3 [Reporting 11/10 AMC] http://www.estimize.com/intro/neo?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.